top of page

News.

June 8-11, 2024

We are thrilled to announce that our lab will be presenting groundbreaking research at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 in Toronto, Canada. Join us to explore our latest advancements and innovations in the field!

April 17-12, 2024

Our lab was excited to organize and present several groundbreaking research projects at the 2nd Singapore Molecular Imaging and Theranostics Symposium (MITS 2024).

The project titled "Precision Risk Stratification in Prostate Cancer: Unveiling Tumor Subregions through MRI-Based Habitat-Driven Radiomics Model for Enhanced Treatment Guidance" was presented by Yang Qiu, Huan Liu, Xin Shu, Yunfan Liu, Xiaofeng Qiao, Jingjing Zhang, and Xiaojing He. This study developed a habitat-driven radiomics model using MRI to assess spatial heterogeneity within prostate cancer tumors. The model, which combines sub-regional and conventional radiomic features, demonstrated strong predictive performance and significant correlations with PSA, Gleason Grade Group, and T-stage, aiding in precise treatment and monitoring of prostate cancer.

In "Theranostic Application of 177Lu-Labeled Anti-Claudin-18.2 Humanized VHH-Based Recombinant Antibody in Gastric Cancer Mouse Xenograft Model", Zhenni Wei, Bingyu Li, Cuicui Li, Tianzhi Zhao, Xiaoyuan Chen, and Jingjing Zhang developed 177Lu-labeled anti-claudin-18.2 Zolbetuximab and its humanized VHH-based recombinant antibody (VHH-Fc) for SPECT imaging and radioimmunotherapy in gastric cancer models. Results showed significant tumor-specific uptake and detection efficiency of CLDN18.2-overexpressing tumors, indicating high potential for clinical translation and offering a promising new treatment option for gastric cancer.

"Synthesis, Preclinical Assessment, and a Pilot Clinical Trial of 177Lu-LNC1010 for Metastatic Neuroendocrine Tumor Therapy" was presented by Xuejun Wen, Wei Guo, Pengfei Xu, Jingjing Zhang, Haojun Chen, and Xiaoyuan Chen. This study reported results of 177Lu-LNC1010, a novel EB conjugated SSTR2-targeting radiopharmaceutical, to enhance tumor uptake and improve therapy for neuroendocrine tumors (NETs). 177Lu-LNC1010 demonstrated high binding affinity and targeting specificity, with significant tumor uptake and prolonged retention, indicating promising therapeutic potential for NETs.

Finally, the project "Comparison of Diagnostic PET Imaging between 68Ga-FAPI and 18F-FDG for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radionuclide Therapy", presented by Rongxi Wang, Jiarou Wang, Jialin Xiang, Linlin Li, Xingtong Peng, Xiaoyuan Chen, Zhaohui Zhu, and Jingjing Zhang, compared the performance of 68Ga-FAPI-04 and 18F-FDG PET/CT imaging in detecting recurrent/metastatic solitary fibrous tumors (SFTs) and explored the preliminary application of FAP-targeted radionuclide therapy with 177Lu-EB-FAPI. The results demonstrated that 68Ga-FAPI-04 PET/CT detected significantly more lesions and showed higher uptake values in most organs compared to 18F-FDG, indicating its potential as a promising diagnostic and therapeutic agent for SFTs.

bottom of page